Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion.
Eli Lilly reported a robust second-quarter earning and revenue that surpassed analysts' expectations, with its full-year sales outlook also increasing. The pharmaceutical company now anticipates 2026 revenue between $85 billion and $87 billion, a slight rise from its previous forecast of $82 billion to $85 billion. Eli Lilly's projected full-year adjusted profit per share is now between $35.50 and $36.50, compared to the earlier range of $35.50 to $37.
The company raised its underlying profit guidance by $2.78 per share, however, this was offset by $3.03 per share in charges linked to deals made in the quarter. Shares of Lilly surged more than 5% in premarket trading on Wednesday, driven by robust demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro.
The company expects significant M&A activity as it capitalizes on the financial windfall generated by its obesity and diabetes drugs.
Written by urgent.news from CNBC's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.
